SK Biopharmaceuticals Co., Ltd. (KRX:326030)

South Korea flag South Korea · Delayed Price · Currency is KRW
124,600
-900 (-0.72%)
At close: Dec 30, 2025
20.04%
Market Cap9.76T
Revenue (ttm)675.41B
Net Income (ttm)320.47B
Shares Out78.31M
EPS (ttm)4,092.19
PE Ratio30.45
Forward PE39.32
Dividendn/a
Ex-Dividend Daten/a
Volume99,454
Average Volume174,785
Open126,100
Previous Close125,500
Day's Range123,900 - 126,400
52-Week Range86,900 - 144,100
Beta0.84
RSI38.64
Earnings DateFeb 4, 2026

About SK Biopharmaceuticals

SK Biopharmaceuticals Co., Ltd., a pharmaceutical company, engages in the research, development, and commercialization of drugs for the treatment of central nervous system disorders. The company offers Cenobamate, an anti-seizure medication for the treatment of epilepsy and Solriamfetol medication. It develops Carisbamate that is in Phase 3 trials to treat lennox-gastaut syndrome; Relenopride, which is in Phase 2 clinical trials for treatment of rare neurological disease; SKL24741, which is in Phase 1 clinical trials for the treatment of epilep... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 1993
Employees 246
Stock Exchange Korea Stock Exchange
Ticker Symbol 326030
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.